CureVac NV (CVAC) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $4.66
• Market Cap: $1.05B
• P/E Ratio: 6.96
• EPS: $0.67
• 52-Week High: $5.72
• 52-Week Low: $2.48

Market Sentiment

CureVac NV currently has a Bullish sentiment score of 0.24.

About CureVac NV

CureVac NV (CVAC) is a leading clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, focused on developing innovative therapies based on messenger ribonucleic acid (mRNA) technology. The company is committed to addressing significant unmet medical needs by advancing a diverse pipeline of mRNA-based vaccines and therapeutics across various indications, including infectious diseases and oncology. With its robust scientific platform and strategic partnerships, CureVac is w...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for CureVac NV and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CVAC pay dividends?

CureVac NV (CVAC) does not currently pay a regular dividend.

What is CVAC's P/E ratio?

CureVac NV has a price-to-earnings (P/E) ratio of 6.96.

What is CVAC's market cap?

CureVac NV (CVAC) has a market capitalization of $1.05B with a current stock price of $4.66.